Towards evidence based medicine for paediatricians: What are the options for treating latent TB infection in children?

Amanda Gwee, Benjamin Coghlan, Nigel Curtis

Research output: Contribution to journalLetterOther

13 Citations (Scopus)

Abstract

Children with LTBI have a significant risk of developing active TB without treatment, including those that have been BCG-immunised.1 Progression to active TB has been reported in up to 40 of infected infants.2 Recommendations for the treatment of LTBI in children vary: the Centers for Disease Control and Prevention recommend 9 months of isoniazid monotherapy3; the UK NICE guidelines suggest 6 months of isoniazid monotherapy or 3 months of combination therapy with rifampicin plus isoniazid4; and Australian guidelines suggest 6?12 months of isoniazid monotherapy. 5 Isoniazid preventive therapy (IPT) has been reported to have a protective efficacy of up to 90 in compliant patients.6 However, low treatment completion rates which have been reported as low as 65 , limit the effectiveness of IPT.7 Of the 12 studies that met our criteria, 10 compared isoniazid monotherapy with shorter courses of: (i) rifampicin plus isoniazid (RH); (ii) rifampicin plus pyrazinamide (RZ); and (iii) rifampicin monotherapy (R).
Original languageEnglish
Pages (from-to)468 - 473
Number of pages6
JournalArchives of Disease in Childhood
Volume98
Issue number6
DOIs
Publication statusPublished - 2013

Cite this